Status:
COMPLETED
Oral Superoxide Dismutase (GLISODin) to Decrease Melasma Severity.
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
Melasma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Oxidative stress has been reported to play a role in melasma pathophysiology. The objective of the study is to compare oral superoxide dismutase (GLISODin) to placebo, in combination to sunscreen to d...
Eligibility Criteria
Inclusion
- Clinically diagnosed melasma in adult patient
- signed inform consent
Exclusion
- Pregnant women
- Other pigmentary disorder of the afce
- Use of depigmentant agent in the month before the inclusion
- Use of topical steroid, tretinoin, hydroquinone in the month before the inclusion
- Coeliac disease or allergy to gluten
Key Trial Info
Start Date :
April 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03878433
Start Date
April 1 2019
End Date
July 1 2020
Last Update
September 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nice - Dermatology
Nice, Alpes-Maritime, France, 06001